<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Childs Nerv Syst</journal-id>
      <journal-title-group>
        <journal-title>Child's Nervous System</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0256-7040</issn>
      <issn pub-type="epub">1433-0350</issn>
      <publisher>
        <publisher-name>Springer-Verlag</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">20661577</article-id>
      <article-id pub-id-type="pmc">3015198</article-id>
      <article-id pub-id-type="publisher-id">1238</article-id>
      <article-id pub-id-type="doi">10.1007/s00381-010-1238-3</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Multiple primary cranio-spinal tumours in a 13-year-old female with neurofibromatosis type 2 management strategy</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Stachowicz-Stencel</surname>
            <given-names>Teresa</given-names>
          </name>
          <address>
            <phone>+48-58-3492880</phone>
            <fax>+48-58-3492847</fax>
            <email>tsten@gumed.edu.pl</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Synakiewicz</surname>
            <given-names>Anna</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bien</surname>
            <given-names>Ewa</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Adamkiewicz-Drozynska</surname>
            <given-names>Elzbieta</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wybieralska-Dubaniewicz</surname>
            <given-names>Miroslawa</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Balcerska</surname>
            <given-names>Anna</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Department of Paediatrics, Haematology, Oncology and Endocrinology, Medical University of Gdansk, 7 Debinki Street, 80-211 Gdansk, Poland </aff>
        <aff id="Aff2"><label>2</label>Department of Radiology, Medical University of Gdansk, Gdansk, Poland </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>27</day>
        <month>7</month>
        <year>2010</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>27</day>
        <month>7</month>
        <year>2010</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2011</year>
      </pub-date>
      <volume>27</volume>
      <issue>1</issue>
      <fpage>175</fpage>
      <lpage>178</lpage>
      <history>
        <date date-type="received">
          <day>29</day>
          <month>1</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>15</day>
          <month>7</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2010</copyright-statement>
      </permissions>
      <abstract>
        <sec>
          <title>Introduction</title>
          <p>Neurofibromatosis type 2 (NF2) is an inherited, rare autosomal dominant syndrome characterised by the development of multiple benign cranial and spinal tumours, peripheral neuropathy, ophthalmological and cutaneous lesions. Herein, we report one case of NF2 treated with multivariate chemotherapy.</p>
        </sec>
        <sec>
          <title>Material and methods</title>
          <p>A 13-year-old female presented with multiple cranio-spinal tumours in MRI. First symptoms were progressive changes in vision, left-sided paresis, unilateral sensorineural hearing loss, and left hypoglossal nerve paresis<bold>.</bold> The patient underwent palliative, partial surgical resection of the tumour which was located in a posterior fossa. Histopathological examination showed a psammomatous meningioma located near the great foramen and schwannomas of VIII nerve in the cerebello-pontine angle. Clinical and radiological examination revealed a rapid progression of the disease. As such, multivariate chemotherapy was used. The patient died 4&#xA0;years after diagnosis.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>NF2 patients with multiple tumours at diagnosis may not be treatable with surgery alone and, as a result, presentation with such a disease in childhood results in poor prognosis. The unification of management strategies in NF2 patients is highly desirable.</p>
        </sec>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Children</kwd>
        <kwd>Cranio-spinal tumours</kwd>
        <kwd>Neurofibromatosis type 2</kwd>
        <kwd>Prognosis</kwd>
        <kwd>Treatment</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer-Verlag 2011</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p>Neurofibromatosis type 2 (NF2) is an inherited, rare autosomal dominant syndrome characterized by the development of multiple benign cranial and spinal tumours (schwannomas, meningiomas, ependymomas), peripheral neuropathy, ophthalmological and cutaneous lesions [<xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR3">3</xref>]. Tumours associated with NF2 are caused by the inactivation of both alleles of the NF2 tumour-suppressor gene that has been localised on the chromosome 22q12, by mutation or allele loss [<xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR5">5</xref>]. Recent evidence suggests that between 20% and 30% of NF2 cases without a family history of the disease are mosaic for the underlying disease-causing mutation and more than 50% of patients represent new mutations [<xref ref-type="bibr" rid="CR4">4</xref>]. The disorder appears in one of 25,000 live births [<xref ref-type="bibr" rid="CR1">1</xref>]. About 10% of NF2 patients are under the age of 10&#xA0;years old. Among patients with NF2, 18% present with symptoms of the disease at the age of 15&#xA0;years or less [<xref ref-type="bibr" rid="CR6">6</xref>]. Although most tumours in the central nervous system in NF2 are slow growing, they may grow faster during childhood. In this situation, the prognosis is often poor [<xref ref-type="bibr" rid="CR7">7</xref>]. The development of new tumours is likely in patients with NF2, even after surgery [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. In these situations, a new management strategy and early diagnosis are necessary.</p>
      <p>In this report, we describe the treatment of a 13-year-old female with NF2 who had multiple types of primary tumours in the brain and spinal canal.</p>
    </sec>
    <sec id="Sec2">
      <title>Case report</title>
      <p>A 13-year-old female was admitted to the Department of Paediatric Oncology because of complaints of progressive changes in vision, left-sided paresis, unilateral sensorineural hearing loss, left hypoglossal nerve paresis and difficulties in learning at school over a period of 6&#xA0;months. The physical examination showed one caf&#xE9;-au-lait spot on the left upper leg (greater than 10&#xA0;cm in diameter) and one on the left scapula, schwannomas of the forearms and dysmorfic face (depressed nasal root, hypertelorism, small and downward slanting palpebral fissures, short philtrum with a tented upper lip and mandibular hypoplasia). Neurological examination revealed bilateral Babinski's reflex, left-sided muscular atrophy and a deflection of the tongue to the left. Magnetic resonance imaging (MRI) of the brain and spinal canal revealed multiple cranial nerves tumours: V-trigeminal nerve, bilateral vestibular schwannomas and right-sided meningioma, and meningioma in the area of the optic nerve (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1a, b</xref>). In the posterior cranial fossa, the huge focus involving the foramen magnum was described as schwannomas of VIII nerve (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). Multiple spinal canal nodules, involving L5-S1 level, were observed (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>). The patient underwent palliative, partial surgical resection of the posterior fossa tumour. Histopathological examination showed psammomatous meningioma localised near the foramen magnum and schwannoma in the cerebello-pontine angle.
<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p><bold>a</bold> Contrast-enhanced conventional T1-weighted MR image: neuromas of the V and VIII nerve and sagittal right-sided meningioma. <bold>b</bold> Contrast-enhanced transversal T1-weighted MR image: the optic nerve glioma</p></caption><graphic xlink:href="381_2010_1238_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig.&#xA0;2</label><caption><p>In the posterior cranial fossa, bilateral pathological solid masses located in pontocerebellar cisterns, which extend to the auditory meatus; intensive contrast enhancement MR image&#x2014;schwannomas of the VIII nerve</p></caption><graphic xlink:href="381_2010_1238_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig.&#xA0;3</label><caption><p>Contrast-enhanced T1-weighted MR image: numerous intradural spinal canal nodules and small tumours in intervertebral foramen on the right side at level L5-S1</p></caption><graphic xlink:href="381_2010_1238_Fig3_HTML" id="MO3"/></fig></p>
      <p>Following the operation, an increased paresis of lower limbs and neurogenic bladder was observed. The excision of the Th11-Th12 tumour was performed. Histopathology proved meningioma. Staphylococcus sepsis and acute renal failure were the side effects after surgery.</p>
      <p>She finished the treatment with clinical success.</p>
      <p>Fourteen months later, progression of the disease was stated. Bilateral deafness, facial nerve paresis, a deflection of the tongue to the right, left eye-ball oedema, visual disorders and ape hand were all observed.</p>
      <p>She received chemotherapy (vinblastin 6&#xA0;mg/m<sup>2</sup> every 2&#xA0;weeks for 3&#xA0;months). In the course of performing MRI of the brain and spinal canal, progression of the disease was observed. The general condition of the patient deteriorated. She was presented with difficulties in talking and severe co-ordination disturbances; she was unable to walk in a straight line and had lost the ability to manipulate small objects. The chemotherapy for low-grade gliomas protocol, according to the Memorial Hospital for Children in Warsaw, was administered thereafter. It was comprised of: intensive chemotherapy&#x2013;carboplatin (550&#xA0;mg/m<sup>2</sup>; 1, 4, 7, 10&#xA0;weeks), vincristin (1.5&#xA0;mg/m<sup>2</sup>, 1&#x2013;10&#xA0;week) and maintenance chemotherapy&#x2013;carboplatin with vincristin every 4&#xA0;weeks.</p>
      <p>After 6&#xA0;months, no response to chemotherapy was stated. Due to no possibility to remove the tumour radically, the child was included in a clinical trial. She received Irinotecan in doses of 20&#xA0;mg/m<sup>2</sup> for 10&#xA0;days every 3&#xA0;weeks. In all, nine cycles were administered to the patient. Thanks to Irinotecan, she achieved the clinical stagnation of the disease.</p>
      <p>Following a period of 2&#xA0;years, progression of the disease was once more present. She was treated with temozolomide (150&#xA0;mg/m<sup>2</sup>) for 3&#xA0;months. Finally, our patient died of the progression of the disease 4&#xA0;years after diagnosis.</p>
    </sec>
    <sec id="Sec3">
      <title>Discussion</title>
      <p>NF2 is an uncommon genetic disorder, which is characterized by an increased risk of benign nervous system tumour development [<xref ref-type="bibr" rid="CR8">8</xref>]. The diagnostic criteria for neurofibromatosis type 2 is bilateral vestibular schwannomas (VS) or family history of NF2 according to first degree family relative, unilateral vestbular schwannomas under 30&#xA0;years old, or any two of the following: meningioma, glioma, schwannoma, juvenile posterior subcapsular lenticular opacities/juvenile cortical cataract [<xref ref-type="bibr" rid="CR9">9</xref>&#x2013;<xref ref-type="bibr" rid="CR12">12</xref>]. Nunes et al. [<xref ref-type="bibr" rid="CR13">13</xref>], presented clinical data on 12 patients with NF2 at age before 18&#xA0;years and in large number with positive family history. One third of the children had hearing impairments and two thirds presented with dysfunctions of the cranial nerve. Radiological examinations revealed cranial meningiomas in 75% of cases, cranial schwannoms in 83%, and spinal cord tumours in 75%. Evans et al. [<xref ref-type="bibr" rid="CR14">14</xref>] showed that at least 18% of NF2 sufferers presented in childhood with isolated features of the disease had no family history. These paediatric patients presented with a more severe course of the disease with multiple tumours. In the study of Bosch et al. [<xref ref-type="bibr" rid="CR15">15</xref>], children with early onset of the disease presented with ophthalmologic symptoms and lower motor neuron extremity weakness and in those with late disease onset, eight nerve impairment was observed. MacCollin and Mautner [<xref ref-type="bibr" rid="CR16">16</xref>] showed that the first ocular manifestation of NF2 in the paediatric population was visual loss or diplopia. Our patient had an atypical onset of this autosomal-dominant disorder. After a few months, she presented with hearing loss, most often related to the development of vestibular schwannomas. Hearing loss, often accompanied by tinnitus, occurs in around 60% of adults and up to 30% of children [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. The MRI scan showed the presence of tumours in the central nervous system and spinal canal. In the literature, there are a great many reports confirming the variety of spinal tumours associated with NF2 [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Bilateral vestibular schwannomas are found in 90&#x2013;95% of patients with NF2. It is reported that more than 99% of VS in NF2 are benign, but they remain an important cause of mortality due to their location [<xref ref-type="bibr" rid="CR1">1</xref>]. Schwannomas can develop along the course of cranial, spinal and peripheral nerves, differently than vestibular. Most often it arises from the oculomotor, trigeminal and facial nerves [<xref ref-type="bibr" rid="CR21">21</xref>]. Schwannomas of spinal nerves may result in discrete peripheral neuropathies. In our patient, the histopathology examination showed meningioma in the posterior cranial fossa, which is the second most common tumour connected with NF2. Intracranial meningiomas appear in 45&#x2013;58% of patients with this disorder and intradural extramedullary spinal meningiomas in 20% [<xref ref-type="bibr" rid="CR2">2</xref>]. Although meningiomas are benign, they may give clinical symptoms, the nature of which are related to their size and anatomical location. It is proven that meningiomas associated with NF2 more frequently have higher proliferative activity and a tendency to form more atypical and anaplastic grades than sporadic meningiomas [<xref ref-type="bibr" rid="CR22">22</xref>].</p>
      <p>The typical treatment strategy for patients with VS is &#x201C;watch and wait then rescan&#x201D;, complete with surgical resection and stereotactic radiotherapy. The authors noted that more than 50% of VS were stable in size, so in this situation the &#x201C;watch and wait then rescan&#x201D; program could be deemed the proper course [<xref ref-type="bibr" rid="CR7">7</xref>]. Of contrary opinion is Brackmann et al. [<xref ref-type="bibr" rid="CR23">23</xref>], regarding situations in which tumours are of less than 3&#xA0;cm in diameter when early surgical management is recommended. It can preserve normal hearing in 30&#x2013;65% and the functioning of facial nerves in 75&#x2013;92% of patients. The role of stereotactic radiotherapy is not yet clearly determined [<xref ref-type="bibr" rid="CR7">7</xref>].</p>
      <p>The majority of meningiomas located in hemispheres and spinal canal can be resected safely and radically. In our patient, the location of the meningioma in the posterior cranial fossa made it impossible to remove completely. In this situation, we agreed that multi-variety protocols should be used. Due to chemotherapy, her overall survival was prolonged.</p>
    </sec>
    <sec id="Sec4">
      <title>Conclusions</title>
      <p>The prognosis in NF2 is still poor. The unification of management strategy in NF2 patients is mandatory in providing effective treatment. Integrated, multidisciplinary care consisting of a neurosurgeon, oncologist, otolaryngologist, neurologist, geneticist, ophthalmologist, pathologist and radiologist is necessary.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Asthagiri</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Parry</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Butman</surname>
              <given-names>JA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Neurofibromatosis type 2</article-title>
          <source>Lancet</source>
          <year>2009</year>
          <volume>373</volume>
          <fpage>1974</fpage>
          <lpage>1986</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(09)60259-2</pub-id>
          <pub-id pub-id-type="pmid">19476995</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Patronas</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Courcoutsakis</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Broley Ch</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Katzman</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>MacCollin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>ParryParry</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>Intramedullary and spinal canal tumors in patients with neurofibromatosis 2; MR imaging findings and correlation with genotype</article-title>
          <source>Radiology</source>
          <year>2001</year>
          <volume>218</volume>
          <fpage>434</fpage>
          <lpage>442</lpage>
          <pub-id pub-id-type="pmid">11161159</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mautner</surname>
              <given-names>VF</given-names>
            </name>
            <name>
              <surname>Baser</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Thakkar</surname>
              <given-names>SD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Vestibular schwannoma growth in patients with neurofibromatosis type 2: a longitudinal study</article-title>
          <source>J Neurosurg</source>
          <year>2002</year>
          <volume>96</volume>
          <fpage>223</fpage>
          <lpage>228</lpage>
          <pub-id pub-id-type="doi">10.3171/jns.2002.96.2.0223</pub-id>
          <pub-id pub-id-type="pmid">11838794</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <mixed-citation publication-type="other">Evans DG (2009) Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 19. doi:<ext-link ext-link-type="uri" xlink:href="http://10.1186/1750-1172-4-16">10.1186/1750-1172-4-16</ext-link></mixed-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harada</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kumon</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hatta</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Sakaki</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ohta</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Neurofibromatosis type2 with multiple primary brain tumors in monozygotic twins</article-title>
          <source>Surg Neurol</source>
          <year>1999</year>
          <volume>51</volume>
          <fpage>528</fpage>
          <lpage>535</lpage>
          <pub-id pub-id-type="doi">10.1016/S0090-3019(97)00487-4</pub-id>
          <pub-id pub-id-type="pmid">10321884</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Janse</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>WF</given-names>
            </name>
            <name>
              <surname>Majoie</surname>
              <given-names>ChBLM</given-names>
            </name>
            <name>
              <surname>Bijlsma</surname>
              <given-names>EK</given-names>
            </name>
          </person-group>
          <article-title>Neurofibromatosis type 2 diagnosed in the absence of vestibular schwannomas. A case report and guidelines for a screening protocol for childrenat risk</article-title>
          <source>Eur J Pediatr</source>
          <year>2001</year>
          <volume>160</volume>
          <fpage>439</fpage>
          <lpage>443</lpage>
          <pub-id pub-id-type="doi">10.1007/s004310100762</pub-id>
          <pub-id pub-id-type="pmid">11475583</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moffat</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Quaranta</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Baguley</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Hardy</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Management strategies in neurofibromatosis type 2</article-title>
          <source>Otology</source>
          <year>2003</year>
          <volume>260</volume>
          <fpage>12</fpage>
          <lpage>18</lpage>
        </mixed-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mautner</surname>
              <given-names>VF</given-names>
            </name>
            <name>
              <surname>Baser</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Thakkar</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Feigen</surname>
              <given-names>UM</given-names>
            </name>
            <name>
              <surname>Friedman</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Kluwe</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Vestibular schwannoma growth in patients with neurofobromatosos type 2: a longitudinal study</article-title>
          <source>J Neurosurg</source>
          <year>2002</year>
          <volume>96</volume>
          <fpage>223</fpage>
          <lpage>228</lpage>
          <pub-id pub-id-type="doi">10.3171/jns.2002.96.2.0223</pub-id>
          <pub-id pub-id-type="pmid">11838794</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reed</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Gutmann</surname>
              <given-names>DH</given-names>
            </name>
          </person-group>
          <article-title>Tumorigenesis in neurofibromatosis: new insights and potential therapies</article-title>
          <source>Trends Mol Med</source>
          <year>2001</year>
          <volume>4</volume>
          <fpage>157</fpage>
          <lpage>162</lpage>
          <pub-id pub-id-type="doi">10.1016/S1471-4914(01)01955-4</pub-id>
          <pub-id pub-id-type="pmid">11286939</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>National Institutes of Health</collab>
          </person-group>
          <article-title>Acoustic neuroma</article-title>
          <source>NIH Consensus Statement</source>
          <year>1991</year>
          <volume>9</volume>
          <fpage>1</fpage>
          <lpage>24</lpage>
        </mixed-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gutmann</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Aylsworth</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Carey</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Korf</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Marks</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pyeritz</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Rubenstein</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Viskochil</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2</article-title>
          <source>JAMA</source>
          <year>1997</year>
          <volume>278</volume>
          <fpage>51</fpage>
          <lpage>57</lpage>
          <pub-id pub-id-type="doi">10.1001/jama.278.1.51</pub-id>
          <pub-id pub-id-type="pmid">9207339</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mautner</surname>
              <given-names>VF</given-names>
            </name>
            <name>
              <surname>Tatagiba</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Guthoff</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Samii</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pulst</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
          <article-title>Neurofibromatosis 2 in the pediatric age group</article-title>
          <source>Neurosurgery</source>
          <year>1993</year>
          <volume>33</volume>
          <fpage>92</fpage>
          <lpage>96</lpage>
          <pub-id pub-id-type="doi">10.1227/00006123-199307000-00014</pub-id>
          <pub-id pub-id-type="pmid">8355853</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nunes</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>MacCollin</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Neurofibromatosis 2 in the pediatric population</article-title>
          <source>J Child Neurol</source>
          <year>2003</year>
          <volume>18</volume>
          <fpage>718</fpage>
          <lpage>724</lpage>
          <pub-id pub-id-type="doi">10.1177/08830738030180101301</pub-id>
          <pub-id pub-id-type="pmid">14649556</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Evans</surname>
              <given-names>DGR</given-names>
            </name>
            <name>
              <surname>Baser</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>O&#x2019;Reilly</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Management of the patient and family with neurofibromatosis 2: a consensus conference statement</article-title>
          <source>Br J Neurosurg</source>
          <year>2005</year>
          <volume>1</volume>
          <fpage>5</fpage>
          <lpage>12</lpage>
          <pub-id pub-id-type="doi">10.1080/02688690500081206</pub-id>
          <pub-id pub-id-type="pmid">16147576</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bosch</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Boltshauser</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Harpes</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Landau</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Ophthalmologic findings and long-term course in patients with neurofibromatosis type 2</article-title>
          <source>Am J Ophthalmol</source>
          <year>2006</year>
          <volume>141</volume>
          <fpage>1068</fpage>
          <lpage>1077</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ajo.2005.12.042</pub-id>
          <pub-id pub-id-type="pmid">16765675</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>MacCollin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mautner</surname>
              <given-names>VF</given-names>
            </name>
          </person-group>
          <article-title>The diagnosis and management of neurofibromatosis 2 in childhood</article-title>
          <source>Semin Pediatr Neurol</source>
          <year>1998</year>
          <volume>5</volume>
          <fpage>243</fpage>
          <lpage>252</lpage>
          <pub-id pub-id-type="doi">10.1016/S1071-9091(98)80003-X</pub-id>
          <pub-id pub-id-type="pmid">9874852</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dow</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Biggs</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Gillespie</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ramsden</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>King</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Spinal tumors in neurofibromatosos type 2. Is emerging knowledge of genotype predictive of natural history?</article-title>
          <source>J Neurosurg Spine</source>
          <year>2005</year>
          <volume>2</volume>
          <fpage>574</fpage>
          <lpage>579</lpage>
          <pub-id pub-id-type="doi">10.3171/spi.2005.2.5.0574</pub-id>
          <pub-id pub-id-type="pmid">15945431</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ruggieri</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Iannetti</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Polizzi</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Earliest clinical manifestations and natural history of neurofibramatosis type 2 (NF2) in childhood: a study of 24 patients</article-title>
          <source>Neuropediatrics</source>
          <year>2005</year>
          <volume>36</volume>
          <fpage>21</fpage>
          <lpage>34</lpage>
          <pub-id pub-id-type="doi">10.1055/s-2005-837581</pub-id>
          <pub-id pub-id-type="pmid">15776319</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mautner</surname>
              <given-names>VF</given-names>
            </name>
            <name>
              <surname>Tatagiba</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lindenau</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Spinal tumors in patients with neurofibramatosis type 2: MR imaging study of frequency, multiplicity and variety</article-title>
          <source>AJR Am J Roentgenol</source>
          <year>1995</year>
          <volume>165</volume>
          <fpage>951</fpage>
          <lpage>955</lpage>
          <pub-id pub-id-type="pmid">7676998</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pascual-Castroviejo</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Pascual-Pascual</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Via&#xF1;o</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Neurofibromatosis type 2 (NF2). Study of 7 patients</article-title>
          <source>Neurologia</source>
          <year>2009</year>
          <volume>24</volume>
          <fpage>457</fpage>
          <lpage>461</lpage>
          <pub-id pub-id-type="pmid">19921555</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fisher</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Doherty</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Lev</surname>
              <given-names>NH</given-names>
            </name>
            <name>
              <surname>Slattery</surname>
              <given-names>WH</given-names>
              <suffix>III</suffix>
            </name>
          </person-group>
          <article-title>Distribution of nonvestibular cranial nerve schwannomas in neurofibromatosis 2</article-title>
          <source>Otol Neurotol</source>
          <year>2007</year>
          <volume>28</volume>
          <fpage>1083</fpage>
          <lpage>1190</lpage>
          <pub-id pub-id-type="doi">10.1097/MAO.0b013e31815a8411</pub-id>
          <pub-id pub-id-type="pmid">18043434</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Perry</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Giannini</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Raghawan</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases</article-title>
          <source>J Neuropath Exp Neurol</source>
          <year>2001</year>
          <volume>60</volume>
          <fpage>994</fpage>
          <lpage>1003</lpage>
          <pub-id pub-id-type="pmid">11589430</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brackmann</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Fayad</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Slattery</surname>
              <given-names>WH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Early proactive management of vestibular schwannomas in neurofibromatosis type 2</article-title>
          <source>Neurosurgery</source>
          <year>2001</year>
          <volume>49</volume>
          <fpage>274</fpage>
          <lpage>283</lpage>
          <pub-id pub-id-type="doi">10.1097/00006123-200108000-00007</pub-id>
          <pub-id pub-id-type="pmid">11504103</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
